SAM 2025
BackOAS3 - Oral Abstract Session 3 – Urticaria/Angioedema
Friday 28 Mar, 13:15 PM -
14:45 PM Bilbao, Spain
Room 0C
Oral Abstract Session
13:15
OA-15
Association of Antinuclear Antibodies with Different Phenotypes of Chronic Urticaria
13:27
OA-16
Beyond the Rash: How Omalizumab Shapes Mental Health Outcomes in Chronic Spontaneous Urticaria
13:39
OA-17
Description of Clinical Features and Triggers in Hereditary Angioedema Attacks Associated with Coagulation Factor XII Mutations
13:51
OA-18
Evolution in Acute Management of Hereditary Angioedema due to C1 inhibitor deficiency (HAE-C1INH)
14:03
OA-19
Short- and Long-Term Prophylaxis in Hereditary Angioedema: Real-World Insights
14:15
OA-20
Benralizumab in Omalizumab refractory chronic spontaneous urticaria - A Case Series of 4 Patients in Portugal
14:27
OA-21
Comparison of baseline clinical characteristics of chronic spontaneous urticaria patients receiving omalizumab, with and without concomitant angioedema
